Addiction Clinics Market Pricey, Unproven Treatments To Desperate Patients
An amino acid infusion called NAD is not approved by the FDA to treat addiction. Yet patients with addiction can be desperate enough to try it, at prices as high as $15,000.
Drug Costs
341-360 of 705 results
-
-
Readers And Tweeters Take Dialysis Providers To Task: Nowhere But In The USA
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
KHN鈥檚 鈥榃hat The Health?鈥: All About Medicare
Before 鈥淢edicare for All,鈥 there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHN鈥檚 Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
-
Shopping Abroad For Cheaper Medication? Here鈥檚 What You Need To Know
Americans routinely skirt federal law by crossing into Canada and Mexico or tapping online pharmacies abroad to purchase prescription medications at a fraction of the price they would pay at home. Is it safe? Not necessarily. Here鈥檚 some advice.
-
KHN鈥檚 鈥榃hat The Health?鈥: We Answer Your Questions
You asked about drug prices, the 鈥淐adillac tax鈥 on generous insurance plans and why Americans don鈥檛 know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN鈥檚 Julie Rovner to answer those questions.
-
KHN鈥檚 鈥榃hat The Health?鈥: Gun Violence And The Politics Of Public Health
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHN鈥檚 Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for 鈥渆xtra credit,鈥 the panelists recommend their favorite health stories of the week.
-
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as 鈥渁uthorized generics,鈥 in-house spinoffs of brand-name drugs quietly undermine the competition.
By Jay Hancock and Sydney Lupkin -
Podcast
KHN鈥檚 鈥榃hat The Health?鈥: Deciphering The Democrats鈥 Health Debate
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHN鈥檚 Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
-
California Bill Would Fight Deals That Delay Generic Drugs
As California Attorney General Xavier Becerra cracks down on pharmaceutical companies he said paid competitors to delay generic versions of their drugs, he鈥檚 also pushing for legislation that would give his department tools to catch more of them. It鈥檚 the first of its kind in the nation.
-
Trump Administration 鈥極pen For Business鈥 On Drug Imports From Canada
HHS secretary announces a preliminary plan Wednesday to allow Americans to import certain lower-cost drugs from Canada. Manufacturers were quick to criticize the plan, saying it does not guarantee the safety of drugs coming into the country.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Klobuchar Says D.C. Has Enough Drug Lobbyists To Double-Team Lawmakers
The drug industry has the biggest lobbying war chest.
-
GOP Senators Distance Themselves From Grassley And Trump鈥檚 Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
-
KHN鈥檚 鈥榃hat The Health?鈥: Cue The Drug Price Debate
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN鈥檚 Julie Rovner to discuss this, plus court actions on health issues.
-
A Conservative Group Paints Trump鈥檚 Drug-Pricing Experiment As 鈥楽ocialist.鈥 Is It?
The Americans for Tax Reform commercial takes too broad a brush against an initiative under consideration by the administration that would be part of the president鈥檚 promise to curb high drug prices.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHN鈥檚 鈥榃hat The Health?鈥: Biden Doubles Down On Obamacare
Presidential candidate Joe Biden unveiled a health plan intended to provide a more moderate alternative to his competitors鈥 鈥淢edicare for All鈥 plans. It would build on the Affordable Care Act but would go much further. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHN鈥檚 Julie Rovner to discuss this, plus Planned Parenthood鈥檚 very bad week, the U.S. House vote to repeal the health law鈥檚 鈥淐adillac tax鈥 on generous health plans, and the reduction in deaths from opioids.
-
A ‘No-Brainer’? Calls Grow For Medicare To Cover Anti-Rejection Drugs After Kidney Transplant
Banking on new cost estimates, a bipartisan coalition in Congress is poised to try 鈥 once again 鈥 to end a three-year limit on coverage for lifesaving medication required to keep the organs functioning.
-
Even When HIV Prevention Drug Is Covered, Other Costs Block Treatment
The U.S. Preventive Services Task Force recommended that people who are at high risk of contracting HIV take PrEP, a preventive treatment. The decision means most health plans will be required to cover the drugs without charging patients. But the recommendation doesn鈥檛 apply to the other clinical and lab services people need.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.